DDInter1269 DDInter1845
Nateglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Nateglinide is an amino acid derivative that induces an early insulin response to meals decreasing postprandial blood glucose levels. It should only be taken with meals and meal-time doses should be skipped with any skipped meal. Approximately one month of therapy is required before a decrease in fasting blood glucose is seen. Meglitnides may have a neutral effect on weight or cause a slight increase in weight. The average weight gain caused by meglitinides appears to be lower than that caused by sulfonylureas and insulin and appears to occur only in those naïve to oral antidiabetic agents. Due to their mechanism of action, meglitinides may
A propylamine formed from the cyclization of the side chain of amphetamine. This monoamine oxidase inhibitor is effective in the treatment of major depression, dysthymic disorder, and atypical depression. It also is useful in panic and phobic disorders (From AMA Drug Evaluations Annual, 1994, p311). Tranylcypromine is a racemate comprising equal amounts of (1R,2S)- and (1S,2R)-2-phenylcyclopropan-1-amine with the chiral centers both located on the cylopropane ring. An irreversible monoamine oxidase inhibitor that is used as an antidepressant (INN tranylcypromine).
Nateglinide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Phentermine
Phentermine {u} (Compound) resembles {v} (Compound) Tranylcypromine
Nateglinide {u} (Compound) resembles {v} (Compound) Dextroamphetamine
Dextroamphetamine {u} (Compound) resembles {v} (Compound) Tranylcypromine
Nateglinide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Phendimetrazine
Phendimetrazine {u} (Compound) resembles {v} (Compound) Tranylcypromine
Nateglinide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Phenelzine
Phenelzine {u} (Compound) resembles {v} (Compound) Tranylcypromine
Nateglinide {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Tranylcypromine
Nateglinide {u} (Compound) causes {v} (Side Effect) Asthenia
Asthenia {u} (Side Effect) is caused by {v} (Compound) Tranylcypromine
Nateglinide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Phentermine
Phentermine {u} (Compound) resembles {v} (Compound) Dextroamphetamine
Dextroamphetamine {u} (Compound) resembles {v} (Compound) Tranylcypromine
Nateglinide {u} (Compound) resembles {v} (Compound) Dextroamphetamine
Dextroamphetamine {u} (Compound) resembles {v} (Compound) Phentermine
Phentermine {u} (Compound) resembles {v} (Compound) Tranylcypromine
Nateglinide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Phendimetrazine
Phendimetrazine {u} may lead to a major life threatening interaction when taken with {v} Phentermine
Phentermine {u} (Compound) resembles {v} (Compound) Tranylcypromine
Nateglinide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Phenylpropanolamine
Phenylpropanolamine {u} may lead to a major life threatening interaction when taken with {v} Phentermine
Phentermine {u} (Compound) resembles {v} (Compound) Tranylcypromine
Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Phentermine and Phentermine (Compound) resembles Tranylcypromine (Compound)
Nateglinide (Compound) resembles Dextroamphetamine (Compound) and Dextroamphetamine (Compound) resembles Tranylcypromine (Compound)
Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Phendimetrazine and Phendimetrazine (Compound) resembles Tranylcypromine (Compound)
Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Phenelzine and Phenelzine (Compound) resembles Tranylcypromine (Compound)
Nateglinide (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Tranylcypromine (Compound)
Nateglinide (Compound) causes Asthenia (Side Effect) and Asthenia (Side Effect) is caused by Tranylcypromine (Compound)
Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Phentermine and Phentermine (Compound) resembles Dextroamphetamine (Compound) and Dextroamphetamine (Compound) resembles Tranylcypromine (Compound)
Nateglinide (Compound) resembles Dextroamphetamine (Compound) and Dextroamphetamine (Compound) resembles Phentermine (Compound) and Phentermine (Compound) resembles Tranylcypromine (Compound)
Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Phendimetrazine and Phendimetrazine may lead to a major life threatening interaction when taken with Phentermine and Phentermine (Compound) resembles Tranylcypromine (Compound)
Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Phenylpropanolamine and Phenylpropanolamine may lead to a major life threatening interaction when taken with Phentermine and Phentermine (Compound) resembles Tranylcypromine (Compound)